

# christian Neri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4210547/publications.pdf>

Version: 2024-02-01

82  
papers

11,611  
citations

126708

33  
h-index

85405

71  
g-index

92  
all docs

92  
docs citations

92  
times ranked

19024  
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	5.5	6,961
2	Absence of effects of Sir2 overexpression on lifespan in <i>C. elegans</i> and <i>Drosophila</i> . <i>Nature</i> , 2011, 477, 482-485.	13.7	574
3	Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. <i>Nature Genetics</i> , 2005, 37, 349-350.	9.4	479
4	De novo mutations in the gene encoding the synaptic scaffolding protein <i>SHANK3</i> in patients ascertained for schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 7863-7868.	3.3	361
5	SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 7927-7932.	3.3	304
6	<i>C. elegans</i> neurons jettison protein aggregates and mitochondria under neurotoxic stress. <i>Nature</i> , 2017, 542, 367-371.	13.7	301
7	Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HS1b and transglutaminase. <i>Journal of Clinical Investigation</i> , 2006, 116, 1410-1424.	3.9	211
8	Expanded polyglutamines in <i>Caenorhabditis elegans</i> cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13318-13323.	3.3	199
9	Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14912-14917.	3.3	180
10	Revolution of Alzheimer Precision Neurology. <i>Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease</i> , 2018, 64, S47-S105.	1.2	122
11	Plasma amyloid $\hat{A}\beta$ 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.4	122
12	The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 1811-6.	3.3	89
13	AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease. <i>Human Molecular Genetics</i> , 2016, 25, 1043-1058.	1.4	87
14	Neuronal identity genes regulated by super-enhancers are preferentially down-regulated in the striatum of Huntington's disease mice. <i>Human Molecular Genetics</i> , 2015, 24, 3481-3496.	1.4	84
15	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018, 14, 1204-1215.	0.4	79
16	CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease. <i>Brain</i> , 2019, 142, 2432-2450.	3.7	71
17	Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2712-2717.	3.3	69
18	Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. <i>Human Molecular Genetics</i> , 2008, 17, 2108-2117.	1.4	64

#	ARTICLE	IF	CITATIONS
19	Dietary Restriction: Standing Up for Sirtuins. <i>Science</i> , 2010, 329, 1012-1013.	6.0	63
20	Huntingtin-Interacting Protein 1 Influences Worm and Mouse Presynaptic Function and Protects <i>Caenorhabditis elegans</i> Neurons against Mutant Polyglutamine Toxicity. <i>Journal of Neuroscience</i> , 2007, 27, 11056-11064.	1.7	61
21	The Oxygen Paradox, the French Paradox, and age-related diseases. <i>GeroScience</i> , 2017, 39, 499-550.	2.1	59
22	Cell-Type-Specific Gene Expression Profiling in Adult Mouse Brain Reveals Normal and Disease-State Signatures. <i>Cell Reports</i> , 2019, 26, 2477-2493.e9.	2.9	55
23	Integration of $\beta$ -Catenin, Sirtuin, and FOXO Signaling Protects from Mutant Huntingtin Toxicity. <i>Journal of Neuroscience</i> , 2012, 32, 12630-12640.	1.7	54
24	Neuron Dysfunction Is Induced by Prion Protein with an Insertional Mutation via a Fyn Kinase and Reversed by Sirtuin Activation in <i>Caenorhabditis elegans</i> . <i>Journal of Neuroscience</i> , 2010, 30, 5394-5403.	1.7	51
25	Large-scale functional RNAi screen in <i>C. elegans</i> identifies genes that regulate the dysfunction of mutant polyglutamine neurons. <i>BMC Genomics</i> , 2012, 13, 91.	1.2	50
26	CA150 Expression Delays Striatal Cell Death in Overexpression and Knock-In Conditions for Mutant Huntingtin Neurotoxicity. <i>Journal of Neuroscience</i> , 2006, 26, 4649-4659.	1.7	48
27	Characterization of Sirtuin Inhibitors in Nematodes Expressing a Muscular Dystrophy Protein Reveals Muscle Cell and Behavioral Protection by Specific Sirtinol Analogues. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1407-1411.	2.9	48
28	NPO3, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2012, 48, 282-289.	2.1	47
29	Meclizine is neuroprotective in models of Huntington's disease. <i>Human Molecular Genetics</i> , 2011, 20, 294-300.	1.4	45
30	Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/ $\beta$ -catenin pathway. <i>Cell Death and Disease</i> , 2013, 4, e821-e821.	2.7	45
31	Association of cerebrospinal fluid $\tau$ synuclein with total and phospho $\tau$ <sup>181</sup> protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 1623-1631.	0.4	45
32	The Wnt Receptor Ryk Reduces Neuronal and Cell Survival Capacity by Repressing FOXO Activity During the Early Phases of Mutant Huntingtin Pathogenicity. <i>PLoS Biology</i> , 2014, 12, e1001895.	2.6	42
33	CAG repeat sequences in bipolar affective disorder: No evidence for association in a french population. <i>American Journal of Medical Genetics Part A</i> , 1998, 81, 338-341.	2.4	38
34	Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimer's disease. <i>Progress in Neurobiology</i> , 2019, 181, 101662.	2.8	38
35	Common disease signatures from gene expression analysis in Huntington's disease human blood and brain. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 97.	1.2	32
36	Survey of CAG/CTG repeats in human cDNAs representing new genes: candidates for inherited neurological disorders. <i>Human Molecular Genetics</i> , 1996, 5, 1001-1009.	1.4	31

#	ARTICLE	IF	CITATIONS
37	The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington's disease. <i>Scientific Reports</i> , 2017, 7, 4014.	1.6	30
38	Loss of glutathione redox homeostasis impairs proteostasis by inhibiting autophagy-dependent protein degradation. <i>Cell Death and Differentiation</i> , 2019, 26, 1545-1565.	5.0	30
39	Detection of polyglutamine expansion in a new acidic protein: a candidate for childhood onset schizophrenia?. <i>Molecular Psychiatry</i> , 1999, 4, 58-63.	4.1	21
40	Role and Therapeutic Potential of the Pro-Longevity Factor FOXO and Its Regulators in Neurodegenerative Disease. <i>Frontiers in Pharmacology</i> , 2012, 3, 15.	1.6	19
41	Morphological remodeling of <i>C. elegans</i> neurons during aging is modified by compromised protein homeostasis. <i>Npj Aging and Mechanisms of Disease</i> , 2016, 2, .	4.5	18
42	Retrospective Evaluation of a Restrictive Transfusion Strategy in Older Adults with Hip Fracture. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1151-1157.	1.3	18
43	Association of plasma YKL-40 with brain amyloid- $\beta^2$ levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	1.5	18
44	Cross-talk between canonical Wnt signaling and the sirtuin-FoxO longevity pathway to protect against muscular pathology induced by mutant PABPN1 expression in <i>C. elegans</i> . <i>Neurobiology of Disease</i> , 2010, 38, 425-433.	2.1	17
45	Association between Cognitive Status before Surgery and Outcomes in Elderly Patients with Hip Fracture in a Dedicated Orthogeriatric Care Pathway. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 145-156.	1.2	17
46	FOXO3 targets are reprogrammed as Huntington's disease neural cells and striatal neurons face senescence with p16 <sup>INK4a</sup> increase. <i>Aging Cell</i> , 2020, 19, e13226.	3.0	17
47	New light on polyglutamine neurodegenerative disorders: interference with transcription. <i>Trends in Molecular Medicine</i> , 2001, 7, 283-284.	3.5	15
48	Genetic and Pharmacological Suppression of Polyglutamine-Dependent Neuronal Dysfunction in <i>Caenorhabditis elegans</i> . <i>Journal of Molecular Neuroscience</i> , 2004, 23, 061-068.	1.1	15
49	Balancing protein similarity and gene co-expression reveals new links between genetic conservation and developmental diversity in invertebrates. <i>Bioinformatics</i> , 2005, 21, 1550-1558.	1.8	15
50	Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines. <i>Breast Cancer Research and Treatment</i> , 1990, 15, 85-93.	1.1	14
51	RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 15, 12-25.	2.3	14
52	Insulin signaling in the aging of healthy and proteotoxically stressed mechanosensory neurons. <i>Frontiers in Genetics</i> , 2014, 5, 212.	1.1	12
53	Anticipation in schizophrenia: No evidence of expanded CAG/CTG repeat sequences in French families and sporadic cases. , 1998, 81, 342-346.		11
54	Biomarkers of vascular dysfunction and cognitive decline in patients with Alzheimer's disease: no evidence for association in elderly subjects. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1133-1141.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Pathways to decoding the clinical potential of stress response FOXO-interaction networks for Huntington's disease: of gene prioritization and context dependence. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 22.	1.7	10
56	CAG/CTG and CCG/GCC Repeats in Human Brain Reference cDNAs: Outcome in Searching for New Dynamic Mutations. <i>Genomics</i> , 1998, 47, 414-418.	1.3	8
57	Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy. <i>Neurology</i> , 2018, 91, e551-e561.	1.5	8
58	Genetic cooperativity in multi-layer networks implicates cell survival and senescence in the striatum of Huntington's disease mice synchronous to symptoms. <i>Bioinformatics</i> , 2020, 36, 186-196.	1.8	8
59	Combining feature selection and shape analysis uncovers precise rules for miRNA regulation in Huntington's disease mice. <i>BMC Bioinformatics</i> , 2020, 21, 75.	1.2	6
60	Shape deformation analysis reveals the temporal dynamics of cell-type-specific homeostatic and pathogenic responses to mutant huntingtin. <i>ELife</i> , 2021, 10, .	2.8	6
61	Biosensing Extracellular Vesicle Subpopulations in Neurodegenerative Disease Conditions. <i>ACS Sensors</i> , 2022, 7, 1657-1665.	4.0	6
62	Identification of Modulators of the C.Âlegans Aryl Hydrocarbon Receptor and Characterization of Transcriptomic and Metabolic AhR-1 Profiles. <i>Antioxidants</i> , 2022, 11, 1030.	2.2	5
63	Preface: Editor's Message for 2016. <i>Current Genomics</i> , 2015, 17, 1-1.	0.7	3
64	Polyglutamine tracts in schizophrenia: gaining new insights. <i>Molecular Psychiatry</i> , 2000, 5, 236-237.	4.1	2
65	Editorial. <i>Current Genomics</i> , 2013, 14, 1-1.	0.7	2
66	Triplets rÃ©pÃ©tÃ©s, maladies neurodÃ©gÃ©nÃ©ratives et psychiatriques : mÃ©canismes et gÃ©nes candidats. <i>Medicine/Sciences</i> , 1996, 12, 1361.	0.0	2
67	Foreword. <i>Current Genomics</i> , 2012, 13, 1-1.	0.7	1
68	Therapeutic potential of longevity modulators as neuroprotective targets in neurodegenerative disease. <i>Research and Perspectives in Alzheimer's Disease</i> , 2013, , 111-120.	0.1	1
69	Current targeted therapeutic strategies for oculopharyngeal muscular dystrophy: from pharmacological to RNA replacement and gene editing therapies. <i>International Journal of Clinical Neurosciences and Mental Health</i> , 2016, , S06.	0.7	1
70	Meet the Editorial Board:. <i>Current Genomics</i> , 2015, 16, 1-1.	0.7	0
71	Editorial:. <i>Current Genomics</i> , 2015, 16, 2-2.	0.7	0
72	B16...Common disease signatures from gene expression analysis in huntington's disease human blood and brain. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A14.2-A15.	0.9	0

#	ARTICLE	IF	CITATIONS
73	B19â€¦RNAseq and chipseq analysis of FOXO3 targets in an huntingtonâ€™s disease human neural stem cell model. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A15.3-A16.	0.9	0
74	B39â€¦Modelling and biological evidence for alteration of extracellular vesicles in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A23.1-A23.	0.9	0
75	A10â€¦Accurate data-driven approaches for modeling MIRNA regulation in the brain of huntingtonâ€™s disease mice. , 2018, , .		0
76	A49â€¦Modeling the dynamics of genetic cooperativity in the brain of huntingtonâ€™s disease mice. , 2018, , .		0
77	A02â€¦Studying the dynamics of DNA damage response in human huntingtonâ€™s disease neural stem cells. , 2018, , .		0
78	I13â€¦Striatal regulation of cholesterol metabolism by CYP46A1 is associated with multiple benefits in huntingtonâ€™s disease knock-in mice models. , 2018, , .		0
79	Expansion de polyglutamines et schizophrÃ©nie : une nouvelle protÃ©ine acide candidate identiÃ©e chez l'enfant malade.. Medecine/Sciences, 1999, 15, 249.	0.0	0
80	B47â€¦Cross-integration of huntingtonâ€™s disease networks. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A25.3-A26.	0.9	0
81	B11â€¦Altered epigenetic signature in the striatum of HD mice and patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A12.3-A13.	0.9	0
82	Journal Current Genomics: News and Editorial Prospects. Current Genomics, 2020, 20, 466-467.	0.7	0